ALDEYRA THERAPEUTICS INC (ALDX) Fundamental Analysis & Valuation

NASDAQ:ALDX • US01438T1060

Current stock price

1.555 USD
+0 (+0.32%)
Last:

This ALDX fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. ALDX Profitability Analysis

1.1 Basic Checks

  • In the past year ALDX has reported negative net income.
  • In the past year ALDX has reported a negative cash flow from operations.
  • In the past 5 years ALDX always reported negative net income.
  • In the past 5 years ALDX always reported negative operating cash flow.
ALDX Yearly Net Income VS EBIT VS OCF VS FCFALDX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -20M -40M -60M

1.2 Ratios

  • ALDX has a Return On Assets of -46.97%. This is comparable to the rest of the industry: ALDX outperforms 48.35% of its industry peers.
  • ALDX has a Return On Equity of -76.49%. This is comparable to the rest of the industry: ALDX outperforms 49.71% of its industry peers.
Industry RankSector Rank
ROA -46.97%
ROE -76.49%
ROIC N/A
ROA(3y)-41.89%
ROA(5y)-36.93%
ROE(3y)-62.16%
ROE(5y)-51.13%
ROIC(3y)N/A
ROIC(5y)N/A
ALDX Yearly ROA, ROE, ROICALDX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -20 -40 -60 -80 -100

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for ALDX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ALDX Yearly Profit, Operating, Gross MarginsALDX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. ALDX Health Analysis

2.1 Basic Checks

  • ALDX has more shares outstanding than it did 1 year ago.
  • The number of shares outstanding for ALDX has been increased compared to 5 years ago.
  • The debt/assets ratio for ALDX is higher compared to a year ago.
ALDX Yearly Shares OutstandingALDX Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M
ALDX Yearly Total Debt VS Total AssetsALDX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M 200M

2.2 Solvency

  • Based on the Altman-Z score of -8.27, we must say that ALDX is in the distress zone and has some risk of bankruptcy.
  • The Altman-Z score of ALDX (-8.27) is worse than 70.49% of its industry peers.
  • ALDX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -8.27
ROIC/WACCN/A
WACCN/A
ALDX Yearly LT Debt VS Equity VS FCFALDX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50M -50M 100M 150M 200M

2.3 Liquidity

  • ALDX has a Current Ratio of 2.58. This indicates that ALDX is financially healthy and has no problem in meeting its short term obligations.
  • ALDX has a worse Current ratio (2.58) than 68.93% of its industry peers.
  • ALDX has a Quick Ratio of 2.58. This indicates that ALDX is financially healthy and has no problem in meeting its short term obligations.
  • ALDX's Quick ratio of 2.58 is on the low side compared to the rest of the industry. ALDX is outperformed by 66.60% of its industry peers.
Industry RankSector Rank
Current Ratio 2.58
Quick Ratio 2.58
ALDX Yearly Current Assets VS Current LiabilitesALDX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M 200M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. ALDX Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 49.48% over the past year.
EPS 1Y (TTM)49.48%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%41.18%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • The Earnings Per Share is expected to grow by 42.56% on average over the next years. This is a very strong growth
  • ALDX is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 51.58% yearly.
EPS Next Y15.76%
EPS Next 2Y19.81%
EPS Next 3Y29.34%
EPS Next 5Y42.56%
Revenue Next Year11.82%
Revenue Next 2Y-17.64%
Revenue Next 3Y45.14%
Revenue Next 5Y51.58%

3.3 Evolution

ALDX Yearly Revenue VS EstimatesALDX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2025 2026 2027 2028 2029 2030 2031 2032 50M 100M 150M
ALDX Yearly EPS VS EstimatesALDX Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 1 -1 2 -2

More info and screens

Find the best growth stocksShow best growing peers

1

4. ALDX Valuation Analysis

4.1 Price/Earnings Ratio

  • ALDX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ALDX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ALDX Price Earnings VS Forward Price EarningsALDX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ALDX Per share dataALDX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 0.4 -0.4 0.6

4.3 Compensation for Growth

  • ALDX's earnings are expected to grow with 29.34% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y19.81%
EPS Next 3Y29.34%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. ALDX Dividend Analysis

5.1 Amount

  • ALDX does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

ALDX Fundamentals: All Metrics, Ratios and Statistics

ALDEYRA THERAPEUTICS INC

NASDAQ:ALDX (4/27/2026, 12:47:49 PM)

1.555

+0 (+0.32%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-27
Earnings (Next)08-05
Inst Owners58.51%
Inst Owner Change-0.5%
Ins Owners2.84%
Ins Owner Change2.8%
Market Cap93.58M
Revenue(TTM)N/A
Net Income(TTM)-33.85M
Analysts85
Price Target7.34 (372.03%)
Short Float %10.16%
Short Ratio1.58
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)53.8%
Min EPS beat(2)47.62%
Max EPS beat(2)59.98%
EPS beat(4)4
Avg EPS beat(4)44.4%
Min EPS beat(4)26.01%
Max EPS beat(4)59.98%
EPS beat(8)5
Avg EPS beat(8)-6.06%
EPS beat(12)9
Avg EPS beat(12)11.63%
EPS beat(16)12
Avg EPS beat(16)12.77%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-25.52%
PT rev (3m)-25.52%
EPS NQ rev (1m)-73.79%
EPS NQ rev (3m)-86.67%
EPS NY rev (1m)6.57%
EPS NY rev (3m)6.57%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-56.34%
Revenue NY rev (3m)-17.93%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 2.11
P/tB 2.11
EV/EBITDA N/A
EPS(TTM)-0.49
EYN/A
EPS(NY)-0.32
Fwd EYN/A
FCF(TTM)-0.55
FCFYN/A
OCF(TTM)-0.55
OCFYN/A
SpS0
BVpS0.74
TBVpS0.74
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA -46.97%
ROE -76.49%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-41.89%
ROA(5y)-36.93%
ROE(3y)-62.16%
ROE(5y)-51.13%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.58
Quick Ratio 2.58
Altman-Z -8.27
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)49.48%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%41.18%
EPS Next Y15.76%
EPS Next 2Y19.81%
EPS Next 3Y29.34%
EPS Next 5Y42.56%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year11.82%
Revenue Next 2Y-17.64%
Revenue Next 3Y45.14%
Revenue Next 5Y51.58%
EBIT growth 1Y41.34%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year15.56%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y22.83%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y22.83%
OCF growth 3YN/A
OCF growth 5YN/A

ALDEYRA THERAPEUTICS INC / ALDX Fundamental Analysis FAQ

What is the fundamental rating for ALDX stock?

ChartMill assigns a fundamental rating of 3 / 10 to ALDX.


What is the valuation status of ALDEYRA THERAPEUTICS INC (ALDX) stock?

ChartMill assigns a valuation rating of 1 / 10 to ALDEYRA THERAPEUTICS INC (ALDX). This can be considered as Overvalued.


How profitable is ALDEYRA THERAPEUTICS INC (ALDX) stock?

ALDEYRA THERAPEUTICS INC (ALDX) has a profitability rating of 1 / 10.


What is the financial health of ALDEYRA THERAPEUTICS INC (ALDX) stock?

The financial health rating of ALDEYRA THERAPEUTICS INC (ALDX) is 5 / 10.